Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

clinical trial

- PMLiVE

Novo Nordisk announces positive results for CagriSema in type 2 diabetes

CagriSema improved weight loss and blood glucose control compared to semaglutide alone across all tested doses

- PMLiVE

AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies

Almost three billion people globally are thought to be either overweight or obese

- PMLiVE

Major prostate cancer screening trial launched in UK

The £42m Transform trial will recruit men aged 50-74, with a lower age limit of 45 for some men

- PMLiVE

Physician-driven, AI-supported: addressing the clinical trial access gap

To open up more clinical paths for patients, HCPs need simpler search tools, better access to information and integrated referral systems that fit into their clinical workflows

- PMLiVE

Bioxodes appoints Philippe Monteyne as new chairman of the board

The appointment comes as the company releases phase 2a data for its intracerebral haemorrhage treatment

Woman holding weight loss injection

Why patients drop out of weight management trials and what you can do about it

Discover the key barriers to retention in obesity and weight-management trials and explore actionable, patient-centered strategies to improve engagement, outcomes, and data reliability.

Cuttsy + Cuttsy

- PMLiVE

Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients

Approximately 38.4 million people in the US are affected by diabetes

- PMLiVE

Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa

The company is planning to submit regulatory applications for the candidate by the end of the year

- PMLiVE

Novo Nordisk gains rights to United Laboratories’ triple receptor agonist in deal worth $2bn

UBT251 is in early-stage clinical development for type 2 diabetes, obesity and other diseases

- PMLiVE

Novo shares phase 3 results for obesity candidate CagriSema in diabetes patients

The company is expecting to file for the first regulatory approval of the drug next year

- PMLiVE

Novo Nordisk’s Ozempic granted FDA approval in chronic kidney disease

The progressive condition affects approximately 40% of type 2 diabetes patients

- PMLiVE

Novo shares promising results for high-dose semaglutide in late-stage obesity study

The experimental dose is also being evaluated in adults with obesity and type 2 diabetes

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links